Abstract
Familial chylomicronemia syndrome (FCS) is a rare monogenic autosomal recessive disease caused by loss-of-function mutations in genes involved in chylomicron breakdown through hydrolysis of triglycerides into free fatty acids. Patients are often diagnosed in early childhood with extremely high triglyceride levels and symptoms including abdominal pain, eruptive cutaneous xanthomata, hepatosplenomegaly, and significant cognitive, psychological, and social impairment. The most serious medical condition suffered by FCS patients is recurrent acute pancreatitis. Lipoprotein lipase (LPL) gene mutation accounts for majority of the known pathogenic mutations. Early diagnosis and strict low-fat diet are critical for successful management of the triglyceride concentration to lower the risk of pancreatitis. The true prevalence of FCS in China is unknown and here we report a Chinese female preterm neonate presented with an extremely high triglyceride level of 22.11 mmol/L on day 13 after birth. Clinical and laboratory workup including whole-exome sequencing revealed two novel compound heterozygous LPL mutations (c.406G > C and c.829G > C) that are co-segregated with her non-consanguineous parents, consistent with autosomal recessive inheritance. A diagnosis of FCS based on clinical, biochemical, and genetic ground was made to guide her management.
Introduction
Familial chylomicronemia syndrome (FCS, OMIM 238600) is characterized by very severe hypertriglyceridemia (; ). Multiple symptoms may present starting from an early age, including episodic abdominal pain, eruptive cutaneous xanthomata, and hepatosplenomegaly (). The most severe and life-threatening complication of FCS is acute pancreatitis, which is shown to have a mortality rate of 5–30% in multiple studies (; ). FCS shows a classic autosomal recessive inheritance pattern, and the prevalence in the United States population is approximately 1 in 1,000,000 (). FCS patients are deficient in the clearance of chylomicrons due to homozygous or compound heterozygous loss-of-function mutations in genes that are involved in the catabolism of triglyceride (TG)-rich lipoproteins, including Lipoprotein lipase (LPL), APOC2, GPIHBP1, APOA5, and LMF1. LPL mutations account for 95% of all monogenic mutations associated with FCS (; ). Diagnosis of FCS is a complex process that involves clinical, biochemical, and genetic analysis (). FCS may be underdiagnosed, and its true prevalence is underreported as specialized tests including LPL activity analysis and comprehensive genetic test may not be available when diagnosis is made (; ).
Herein, we report a Chinese female neonate with severe hypertriglyceridemia of 22.11 mmol/L. After clinical and laboratory workup, a genetic etiology was suspected and genetic testing was implemented with parents’ consent.
Case Description
The Chinese baby girl was born at 29 + 1 week by cesarean section weighing 1300 g to her non-consanguineous parents. She is the first child to a 25-year-old, G2P1 mother diagnosed with systemic lupus erythematosus (SLE) during her pregnancy. The family history was otherwise unremarkable. The parents’ lipid profiles were largely within the normal range except for a slight increase of triglyceride for her mother (3.22 mmol/L). Apgar score was 9–10 at 1 min. After birth, she suffered from pneumonia and neonatal respiratory distress syndrome with symptoms including tachypnea, nasal flare, and grunting. She was admitted to NICU and received antibiotic treatment, symptomatic management, and total parenteral nutrition (TPN). She was transitioned to full gastrointestinal feeding on day 15 after birth. On day 13, her blood drawn for routine tests showed signs of chylomicronemia, and serum lipid profile was obtained and revealed severe hypertriglyceridemia (Table 1 and Supplementary Figure S1A). Blood glucose level and thyroid, liver, and kidney function tests were normal. Studies of amino acids and carnitine metabolism were unremarkable. Her markedly elevated triglyceride level was suspected to have a genetic etiology and whole-exome sequencing (WES) was performed after genetic counseling and obtaining informed written consent from the parents. This study was approved by the Scientific Research Ethics Committee of Peking University Shenzhen Hospital [(2019) NO.058].
TABLE 1
| Age (days) | Diet | TG | TC | HDL | LDL |
| (mmol/L) | |||||
| 13 | Preterm Formula Milk | 22.11 | 3.20 | 0.25 | 1.76 |
| (fat: 4.1 g/100 ml, MCT: 40%) | |||||
| 16 | Formula Milk | 15.25 | 3.90 | 0.28 | 2.03 |
| 21 | (fat: 3.4 g/100 ml) | 21.00 | 3.75 | 0.25 | 1.85 |
| 25 | 9.40 | 2.80 | 0.31 | 1.47 | |
| 33 | 10.83 | 2.99 | 0.30 | 1.55 | |
| 36 | 13.57 | 2.06 | 0.19 | 0.97 | |
| 40 | 13.13 | 2.15 | 0.21 | 0.99 | |
| 49 | 14.03 | 2.13 | 0.20 | 0.93 | |
| 67 | Monogen Formula Milk (MCT: 84%) | 2.86 | / | / | / |
| 90 | Monogen Formula Milk: (MCT: 50%) | 10.35 | 3.73 | 0.38 | 2.15 |
| 210 | Monogen Formula Milk: (MCT: 50%) | 7.38 | 6.86 | 2.26 | 0.29 |
Patient’s lipid profile on various diet.
TG, triglyceride (normal range: 0.20–2.31 mmol/L); TC, total cholesterol (normal range: 3.36–6.64 mmol/L); HDL, high-density lipoprotein (normal range: 0.83–1.96 mmol/L); LDL, low-density lipoprotein (2.07–3.1 mmol/L); and MCT, medium-chain triglyceride.
Methods
Whole-Exome Sequencing and Variant Analysis
Genomic DNA was used for WES with SureSelect Human All Exon V6 array on the Illumina HiSeq X Ten platform with PE150 strategy according to the manufacturer’s instructions (). Sequences were aligned to the human reference genome UCSC/hg19 (), and variants were called using the GATK Unified Genotyper with the default setting and annotated using a custom annotator (; ; ). Variants with minor allele frequency >1% were removed. Variants were then filtered into four categories: de novo, homozygous, and two parental compound heterozygous variants. Variants were further filtered according to GeneReviews (NCBI). In silico analysis of variants was performed with open access software, such as SIFT1 and PolyPhen22. Variant interpretation and prioritization were based on the clinical relevance of the gene and the pathogenicity of the variants using ACMG-AMP guidelines (Richards et al., 2015). The suspected variants were confirmed by Sanger sequencing for blood samples obtained from the patient as well as her parents.
Results
Genetic Analysis by WES Revealed Two Novel Compound Heterozygous Mutations in LPL Gene
Variants on genes known to cause severe hypertriglyceridemia such as LPL, APOC2, GPIHBP1, APOA5, and LMF1 were first selected and interpreted. Bioinformatic analysis revealed compound heterozygous missense mutations (c.406G > C p.A136P and c.829G > C p.D277H) in LPL gene. Both variants were neither found in Exome Aggregation Consortium (exac.broadinstitute.org) nor in 1000G3. A c.829G > A (p.A277N) transition was previously reported as a pathogenic mutation, causing a catalytically defective LPL protein (). We performed sequence conservation analysis across different species, and results showed that both newly found missense mutations were highly conserved across species (Mus musculus, Gallus gallus, Takifugu rubripes, Danio rerio, and Xenopus tropicalis; Figure 1B). Molecular modeling of LPL protein with and without two-novel missense mutations using PyMOL software is shown in Figure 1D and suggested that both mutations would cause the protein to fold improperly. Furthermore, the two mutations were predicted to be deleterious by SIFT and “probably damaging” by PolyPhen, respectively. Sanger sequencing of the parents’ DNA showed that they were heterozygous carriers, with the father being a heterozygous carrier of c.406G > C (p.A136P) mutation and the mother being a heterozygous carrier of c.829G > C (p.D277H) mutation (Figures 1A,C). Using the ACMG criteria for assessing pathogenicity, p.A136P and p.D277H were ranked as likely pathogenic.
FIGURE 1
Patient Management and Follow-Up
While in the hospital, the patient was switched from the preterm formula milk to term formula milk to lower her fat intake starting on day 15. Blood TG level decreased from 22.11 mmol/L on day 13 to 14.03 mmol/L on day 49 when she was discharged a day later. After discharge, the patient was advised to be fed on special Monogen formula milk with high medium-chain glycerides (MCT) content and to be followed up by clinicians periodically (Table 1 and Supplementary Figure S1).
Discussion
Chylomicronemia syndrome consists of two distinctive forms: rare monogenic early onset chylomicronemia and more commonly encountered polygenic chylomicronemia of adulthood (; ). The nomenclatures “Familial LPL deficiency,” “Type 1 hyperlipoproteinemia,” or “Familial chylomicronemia syndrome (FCS)” all describe the monogenic form that shows an autosomal recessive inheritance pattern. FCS patients are deficient in chylomicrons clearance, thus suffering from a plethora of symptoms resulting from an extremely high plasma triglyceride level.
Early diagnosis of FCS is extremely important for proper implementation of management strategies that are individually targeted to reduce potential severe consequences of extremely high blood triglycerides, particularly acute, recurrent pancreatitis. Studies have shown that there is a close correlation between acute pancreatitis risk and plasma triglyceride levels, with 3–4% increase of acute pancreatitis risk with every 100 mg/dl increase of TG concentration (; Rashid et al., 2016). As FCS patients often present in early childhood, a delicate balance between ensuring developmental normalcy supported by sufficiency nutrition and reducing dietary fat intake is necessary for a successful long-term management strategy. FCS is frequently misdiagnosed and patients reported seeing on average at least five physicians before a correct diagnosis is made (; ). Such diagnostic odyssey is common in rare disease diagnosis and poses significant psychological, lifestyle, and financial stress to patients and their family members.
Our case is unusual in that the patient was a 29-week preterm neonate with multiple medical complications and presented with extremely severe hypertriglyceridemia. After ruling out other possible causes of TG elevation, a suspicion of genetic etiology led to the decision to perform a comprehensive genetic analysis using WES, whose utility has been demonstrated in rare disease diagnosis (Niguidula et al., 2018). WES is an effective diagnostic tool in detecting point mutations, indels, and small copy number variations in the coding regions. However, WES cannot reliably detect mutations in the non-coding regions, low-level mosaicism, aneuploidy, trinucleotide repeat expansions, or chromosomal structural rearrangements. Studies have shown that WES has a diagnostic yield of around 25–30% in previously undiagnosed rare disease cases (Yang et al., 2013; ). We used WES and subsequent pedigree study to successfully identify two novel compound heterozygous LPL gene mutations, c.406G > C p.A136P and c.829G > C p.D277H, that were each passed down to the patient from her parents. To our knowledge, both mutations were previously unreported in the public database. They most likely result in a reduction in LPL catalytic activity rather than affecting protein synthesis and secretion by structural analysis (Ramasamy, 2016). So far, there has been no epidemiology study of the incidence and prevalence of FCS in China. Our report suggests that FCS can be readily diagnosed in the neonates with proper workup and accurate early diagnosis will be instrumental in setting a lipid-lowering goal to prevent serious complications such as recurrent acute pancreatitis and developmental issues.
Statements
Data availability statement
The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by the Scientific Research Ethics Committee of Peking University Shenzhen Hospital [(2019) NO.058]. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the patient’ parents for the publication of any potentially identifiable images or data included in this article.
Author contributions
YL contributed to the data collection, data interpretation, and genetic counseling. ZL contributed to the study design and writing of the manuscript. FZ and SZ contributed to the clinical data collection and data interpretation. WZ conceived of the study, participated in its design and coordination and revising the article critically for important intellectual content. All authors contributed to the article and approved the submitted version.
Acknowledgments
The authors would like to thank all patients and their families for their participation in this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.00741/full#supplementary-material
Footnotes
1.^https://sift.bii.a-star.edu.sg/
2.^http://genetics.bwh.harvard.edu/pph2/index.shtml
3.^https://www.internationalgenome.org/1000-genomes-browsers
References
1
AuweraG. A.CarneiroM. O.HartlC.PoplinR.AngelG.del Levy-MoonshineA.et al (2013). From FastQ data to high-confidence variant calls: the genome analysis toolkit best practices pipeline.Curr. Protoc. Bioinform.11:43.
2
BeilU.GrundyS. M.CrouseJ. R.ZechL. (1982). Triglyceride and cholesterol metabolism in primary hypertriglyceridemia.Arterioscler. Offic. J. Am. Heart Assoc., Inc.244–57. 10.1161/01.atv.2.1.44
3
BerglundL.BrunzellJ. D.GoldbergA. C.GoldbergI. J.SacksF.MuradM. H. (2012). Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab.972969–2989. 10.1210/jc.2011-3213
4
BrahmA. J.HegeleR. A. (2015). Chylomicronaemia-current diagnosis and future therapies.Nat. Rev. Endocrinol.11352–362. 10.1038/nrendo.2015.26
5
ChenR.ImH.SnyderM. (2015). Whole-exome enrichment with the agilent sureselect human all exon platform.Cold Spring Harb. Protoc.2015:db.rot083659.
6
DavidsonM.StevensonM.HsiehA.AhmadZ.CrowsonC.WitztumJ. L. (2017). The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study.Expert. Rev. Cardiovasc. Ther.15415–423. 10.1080/14779072.2017.1311786
7
DePristoM. A.BanksE.PoplinR.GarimellaK. V.MaguireJ. R.HartlC.et al (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data.Nat. Genet.43491–498.
8
FalkoJ. M. (2018). Familial chylomicronemia syndrome: a clinical guide for endocrinologists.Endocr. Pract.24756–763. 10.4158/ep-2018-0157
9
Feoli-FonsecaJ. C.LévyE.GodardM.LambertM. (1998). Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study.J. Pediatr.133417–423. 10.1016/s0022-3476(98)70280-x
10
FitzgeraldT. W.GeretyS. S.JonesW. D.KogelenbergM.Van KingD. A.McRaeJ.et al (2015). Large-scale discovery of novel genetic causes of developmental disorders.Nature519223–228. 10.1038/nature14135
11
GaudetD.BlomD.BruckertE.StroesE.KasteleinJ.JohnK.et al (2016). Acute pancreatitis is highly prevalent and complications can be fatal in patients with familial chylomicronemia: results from a survey of lipidologist.J. Clin. Lipidol.10680–681. 10.1016/j.jacl.2016.03.048
12
GelrudA.WilliamsK. R.HsiehA.GwosdowA. R.GilstrapA.BrownA. (2017). The burden of familial chylomicronemia syndrome from the patients’ perspective.Expert Rev. Cardiovasc. Ther.15879–887. 10.1080/14779072.2017.1372193
13
GuoQ.LiM.ChenY.HuH.HuW. (2014). Predictors for mortality following acute pancreatitis in children.Pediatr. Surg. Intern.301111–1115. 10.1007/s00383-014-3595-6
14
HegeleR. A.GinsbergH. N.ChapmanM. J.NordestgaardB. G.KuivenhovenJ. A.AvernaM.et al (2014). The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.Lancet Diabetes Endocrinol.2655–666. 10.1016/s2213-8587(13)70191-8
15
KentW. J.SugnetC. W.FureyT. S.RoskinK. M.PringleT. H.ZahlerA. M.et al (2002). The human genome browser at UCSC.Genome Res.12996–1006. 10.1101/gr.229102.
16
MaY.WilsonB. I.BijvoetS.HendersonH. E.CrambE.RoedererG.et al (1992). A Missense mutation (Asp250→Asn) in Exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries.Genomics13649–653. 10.1016/0888-7543(92)90136-g
17
McKennaA.HannaM.BanksE.SivachenkoA.CibulskisK.KernytskyA.et al (2010). The genome analysis toolkit: a mapreduce framework for analyzing next-generation dna sequencing data.Genome Res.201297–1303. 10.1101/gr.107524.110
18
MurphyM. J.ShengX.MacdonaldT. M.WeiL. (2013). Hypertriglyceridemia and acute pancreatitis.JAMA Intern. Med.173162–164.
19
MurthyV.JulienP.GagnéC. (1996). Molecular pathobiology of the human lipoprotein lipase gene.Pharmacol. Therapeut.70101–135. 10.1016/0163-7258(96)00005-8
20
NiguidulaN.AlamilloC.Shahmirzadi MowlaviL.PowisZ.CohenJ. S.Farwell HagmanK. D. (2018). Clinical whole-exome sequencing results impact medical management.Mol. Genet. Genom. Med.61068–1078. 10.1002/mgg3.484
21
RamasamyI. (2016). Update on the molecular biology of dyslipidemias.Clin. Chim. Acta454143–185. 10.1016/j.cca.2015.10.033
22
RashidN.SharmaP. P.ScottR. D.LinK. J.TothP. P. (2016). Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system.J. Clin. Lipidol.10880–890. 10.1016/j.jacl.2016.02.019
23
RichardsS.AzizN.BaleS.BickD.DasS.Gastier-FosterJ.et al (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology.Genet. Med.17405–423. 10.1038/gim.2015.30
24
YangY.MuznyD. M.ReidJ. G.BainbridgeM. N.WillisA.WardP. A.et al (2013). Clinical whole-exome sequencing for the diagnosis of mendelian disorders.N. Engl. J. Med.3691502–1511.
Summary
Keywords
Familial chylomicronemia syndrome, LPL, whole-exome sequencing, hypertriglyceridemia, missense mutation
Citation
Liu Y, Lan Z, Zhao F, Zhang S and Zhang W (2020) Analysis of a Chinese Pedigree With Familial Chylomicronemia Syndrome Reveals Two Novel LPL Mutations by Whole-Exome Sequencing. Front. Genet. 11:741. doi: 10.3389/fgene.2020.00741
Received
09 May 2020
Accepted
22 June 2020
Published
17 July 2020
Volume
11 - 2020
Edited by
Alpo Juhani Vuorio, University of Helsinki, Finland
Reviewed by
Angelo Baldassare Cefalù, University of Palermo, Italy; Patrizia Tarugi, Università degli Studi di Modena e Reggio Emilia, Italy; Mikko Syvänne, University of Helsinki, Finland
Updates
Copyright
© 2020 Liu, Lan, Zhao, Zhang and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wenyong Zhang, zhangwy@sustech.edu.cn
This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.